glp-1 obesity drug news oct 21 2025 Alarming rise in weight loss overdoses GLP-1 receptor agonists show anti-cancer

Retatrutides Phase 2 safety data looks great, but its still awaiting publication of its Phase 3 results and eventual FDA approval

Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle

Through high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based molecular weight identification, standard molecular weight comparison, and characteristic HPLC profiles of the [ 3 H]proline and [ 3 H]BPC157 standards (Supplementary Figure S2), we speculated the structures of these six components and designated them as M1M6 (Table 10)

Pharmacologic interventions with angiotensin converting enzyme inhibitor or AT1 receptor antagonist has proven effective in attenuating scar tissue metabolic activity and minimizing adverse accumulation of fibrous tissue in noninfarcted myocardium

Injections are performed once every two weeks over a three month period and may be repeated if the need for more improvement exists